Trace the medication from the order to the patient's response.

A prescribing review may involve the indication, allergies, age, weight, pregnancy, kidney or liver function, dose, route, frequency, duplicate therapy, interaction, laboratory monitoring, and communication with the patient. A dispensing review may involve the original prescription, pharmacy image, product selected, National Drug Code, strength, quantity, label, counseling, verification, substitution, stock bottle, lot, and pickup record. An administration review may involve medication-reconciliation data, barcode scans, electronic administration records, infusion-pump logs, overrides, waste, handoff, and bedside monitoring.

The disputed event should be stated with precision. Wrong drug, wrong patient, wrong strength, omitted dose, duplicate dose, route, infusion rate, contraindication, interaction, delayed antidote, monitoring failure, contamination, labeling problem, and defective product are not interchangeable theories. Each has different custodians, experts, regulatory materials, and potential defendants.

Potential sources include the prescriber's order and audit history, medication reconciliation, allergy entries, clinical decision-support alerts, override logs, pharmacy intake image, verification record, stock and lot information, label, counseling notation, transaction and pickup data, electronic medication-administration record, barcode scan, automated dispensing cabinet, infusion pump, smart-pump library, laboratory results, poison-control or emergency response, and incident or agency files. Ownership and retention vary by system.

If a product problem is suspected, preserve the container, remaining contents, label, packaging, lot, receipt, photographs, storage history, and chain of custody without altering or testing the item informally. Check official recall and safety material, but do not equate a recall with proof that the specific unit was defective or caused the patient's condition. Drug, device, pharmacist, physician, nurse, facility, and corporate theories require separate analysis.

The standard-of-care question should match the role. A prescriber may be evaluated for selection and monitoring; a pharmacist for processing, verification, dispensing, and counseling. A nurse for administration and monitoring within the actual setting; a facility for a supported direct-negligence theory. And a manufacturer or seller under product-specific law. Internal policies, alerts, barcode systems, and professional guidance may be relevant without defining the civil standard by themselves.

Causation should link dose and timing to the patient's clinical course. The analysis may require serum levels, kidney and liver function, pharmacokinetics, competing medications, underlying disease, later treatment, alternative causes, and whether a prompt response changed the harm. A temporal association or adverse event report does not establish legal cause.

Legal review should verify the prescriber, professional entity, pharmacy permit holder, pharmacist, technician, hospital, nursing facility, product manufacturer, distributor, public entity, Tribal or federal provider, and insurer. License lookup or a facility listing is a research lead, not proof of employment, agency, control, breach, or responsibility. Product claims may raise learned-intermediary, labeling, federal approval, express or implied preemption, seller, alteration, misuse, and repose issues.

The calendar must address the medical or pharmacy claim, product theory, injury and discovery dates, any repose provision, minority or incapacity, public or federal presentment, tribal procedure, record and product retention, survival or wrongful death, and venue or jurisdiction. A regulator's complaint process, a patient-access request, and a civil action are distinct steps.